As for ribociclib, according to the MONALEESA-2 and MONALEES-3 trials, ribociclib demonstrated a significant improvement in the PFS compared to the letrozole and fulvestrant monotherapies, respectively, in advanced HR+/HER-2 negative breast cancer postmenopausal females (20, 21). The gene discussed is ERBB2; the disease is breast carcinoma.